Erythromycin

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

Retrieved on: 
Thursday, December 14, 2023

Antimicrobial resistance happens when microorganisms like bacteria become resistant to the antimicrobials that are designed to kill them.

Key Points: 
  • Antimicrobial resistance happens when microorganisms like bacteria become resistant to the antimicrobials that are designed to kill them.
  • Therefore, the FDA has not verified their safety or effectiveness as part of the animal drug review process or facility inspections.
  • Providing animals with the appropriate drug is more likely to effectively resolve infections and reduce the need for extended treatment with antimicrobials.
  • Self-diagnosis and treatment with unapproved animal antimicrobials could delay effective treatment, allowing infections to become more severe and/or more resistant to antimicrobials.

How do bacteria actually become resistant to antibiotics?

Retrieved on: 
Wednesday, November 8, 2023

“What doesn’t kill me makes me stronger”, originally coined by Friedrich Nietzsche in 1888, is a perfect description of how bacteria develop antibiotic resistance.

Key Points: 
  • “What doesn’t kill me makes me stronger”, originally coined by Friedrich Nietzsche in 1888, is a perfect description of how bacteria develop antibiotic resistance.
  • Contrary to a common belief, antibiotic resistance is not about your body becoming resistant to antibiotics.

How bacteria adapt

  • The ability for bacteria to adapt lies in part with their astonishing rate of reproduction.
  • While most changes are bad, sometimes they can help the bacteria grow in the presence of an antibiotic.
  • This evolution of resistance can be seen by growing bacteria on a large agar plate (a nutrient support that bacteria like to grow on) with zones of increasing antibiotic levels.

They also exchange genetic material

  • The other key mechanism enabling bacterial resistance is the exchange of genetic information between bacteria.
  • In addition to the main chunk of DNA that encodes the bacterial genome, bacteria can host circular DNA snippets called plasmids.
  • Plasmid exchange usually occurs by direct physical contact between bacteria.

4 ways bacteria resist

  • Gram-positive bacteria like Staphylococcus aureus have a thick cell wall enclosing a lipid membrane.
  • Antibiotics can hijack these entry routes, but bacteria can modify the cell wall, cell membrane and entry proteins to block antibiotic penetration.
  • For example, bacteria increase the thickness of the cell wall to resist antibiotics like vancomycin.
  • Bacteria have machinery known as efflux pumps, which regurgitate unwanted molecules from within the bacteria.
  • Bacteria can alter the pump so it is more effective at removing the antibiotic, or they can simply make more pumps.
  • Antibiotics, like most other drugs, generally work by blocking the function of important enzymes within the bacteria.
  • If bacteria alter the target shape by changing the DNA/protein sequence, the antibiotic (key) can no longer bind to its target (lock).

Bacteria vs antibiotics

  • While bacteria have developed mechanisms to resist antibiotics, these adaptations can come at a “fitness” cost.
  • Bacteria may grow more slowly, or can be killed more easily by another antibiotic.
  • This has led to the concept of “collateral sensitivity” to prevent or overcome resistance when treating patients, by using pairs of antibiotics.


Mark Blaskovich receives funding from a range of government, not-for-profit and commercial organisations for research into antibiotic discovery and development. He is affiliated with AAMRNet (Australian Antimicrobial Resistance Network), an organisation promoting improved care and development of antibiotics and antibiotic alternatives.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Monday, October 30, 2023

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Public advisory - Unauthorized health products seized from Yang Sheng Health Food and G&R Ginseng Trading stores in Richmond, B.C., may pose serious health risks

Retrieved on: 
Friday, August 11, 2023

Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.
  • These products are labelled to contain prescription drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Consult a health care professional if you have used any of these products and have health concerns.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.